Literature DB >> 12172248

Endoscopic sinus surgery for inflammatory maxillary sinus disease.

Nicolas Y Busaba1, David Kieff.   

Abstract

OBJECTIVE/HYPOTHESIS: The role of endoscopic sinus surgery for treating chronic maxillary sinusitis is well established. The purpose of the study is to determine the efficacy of endoscopic sinus surgery in the treatment of maxillary sinus inflammatory disease that includes mucoceles, retention cysts, and antrochoanal polyps. STUDY
DESIGN: This is a retrospective review of 32 consecutive patients who underwent endoscopic sinus surgery for mucoceles (n = 21), retention cysts (n = 5), or antrochoanal polyps (n = 6).
METHODS: The medical records were reviewed for patient demographics, presenting symptoms, and type of operation. Surgical outcome was determined by resolution of symptoms, recurrence of disease, and need for revision or additional surgery.
RESULTS: Ethmoidectomy with middle meatal antrostomy was performed in all patients; 28 patients had additional middle turbinectomy. Postoperative follow-up ranged from 6 months to 4 years. The operation resulted in resolution of symptoms and a patent antrostomy on long-term follow-up in all cases of mucoceles. No case required revision surgery. On the other hand, the disease recurred in three patients (60%) with retention cysts and three patients (50%) with antrochoanal polyps despite patent antrostomies. The recurrences occurred 3 to 6 months after the surgery. The recurrent cases of antrochoanal polyps required Caldwell Luc procedures. The three failures in cases of retention cysts were successfully managed with repeated office endoscopic marsupialization through a patent antrostomy.
CONCLUSIONS: Endoscopic sinus surgery is an effective treatment for mucoceles, with favorable long-term outcome. Maxillary retention cysts commonly recur after endoscopic sinus surgery. However, the recurrence can be managed in the office through a patent antrostomy. Endoscopic sinus surgery may be offered as initial surgical treatment for antrochoanal polyps, but a Caldwell Luc operation may be needed for recurrent disease.

Entities:  

Mesh:

Year:  2002        PMID: 12172248     DOI: 10.1097/00005537-200208000-00010

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  8 in total

Review 1.  Radiological imaging of inflammatory lesions in the nasal cavity and paranasal sinuses.

Authors:  H B Eggesbø
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

2.  Endoscopic management of antrochoanal polyps: a single UK centre's experience.

Authors:  Natasha Choudhury; Ahmad Hariri; Hesham Saleh
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-16       Impact factor: 2.503

3.  The effect of the presence of the accessory maxillary ostium on the maxillary sinus.

Authors:  Alper Yenigun; Zeliha Fazliogullari; Cihat Gun; Ismihan Ilknur Uysal; Alaaddin Nayman; Ahmet Kagan Karabulut
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-14       Impact factor: 2.503

4.  Maxillary sinus mucocele: predisposing factors, clinical presentations, and treatment.

Authors:  Mosaad Abdel-Aziz; Hassan El-Hoshy; Khaled Azooz; Nader Naguib; Ahmed Hussein
Journal:  Oral Maxillofac Surg       Date:  2016-11-28

5.  Endoscopic assistance in the diagnosis and treatment of odontogenic maxillary sinus disease.

Authors:  Gregory Venetis; Eleni Bourlidou; Paris Georgios Liokatis; Lampros Zouloumis
Journal:  Oral Maxillofac Surg       Date:  2013-03-19

6.  Maxillary mucocele in a 4-month infant.

Authors:  Lucas Gomes Patrocinio; Priscila Garcia Damasceno; José Antonio Patrocinio
Journal:  Braz J Otorhinolaryngol       Date:  2008 May-Jun

7.  Comparison of clinical characteristics between primary and secondary paranasal mucoceles.

Authors:  Kyung Chul Lee; Nam Hoon Lee
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

8.  Endoscopic sinus surgery for maxillary sinus mucoceles.

Authors:  Fatma Caylakli; Haluk Yavuz; Alper Can Cagici; Levent Naci Ozluoglu
Journal:  Head Face Med       Date:  2006-09-06       Impact factor: 2.151

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.